Use of Immunosuppressive Therapy for Sarcoidosis

NCT ID: NCT02356445

Last Updated: 2017-08-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

2000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-11-30

Study Completion Date

2018-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Retrospective review of the outcome of use of immunosuppressive drugs in treatment of sarcoidosis

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients receiving one or more cytotoxic or other immunosuppressive drug will be observed

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sarcoidosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cytotoxic drug

Patients treated for sarcoidosis

Cytotoxic drug

Intervention Type OTHER

Observe patients versus treatment type

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cytotoxic drug

Observe patients versus treatment type

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Methotrexate, azathioprine, infliximab, Acthar

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Any patient treated for sarcoidosis

Exclusion Criteria

* None
Minimum Eligible Age

15 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Cincinnati

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Robert P Baughman

Professor of Medicine

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Robert P Baughman, MD

Role: PRINCIPAL_INVESTIGATOR

University of Cincinnati

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Cincinnati

Cincinnati, Ohio, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Robert P Baughman, MD

Role: CONTACT

513-584-5225

Felicia Thompson

Role: CONTACT

513-584-5226

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Robert P Baughman, MD

Role: primary

513-584-5225

Elyse E Lower

Role: backup

513-584-3829

References

Explore related publications, articles, or registry entries linked to this study.

Baughman RP, Kotzin J, Lower EE. The Value of a Patient Global Assessment in Management of Sarcoidosis. Lung. 2021 Aug;199(4):357-362. doi: 10.1007/s00408-021-00455-5. Epub 2021 Jul 13.

Reference Type DERIVED
PMID: 34255140 (View on PubMed)

Zhou Y, Lower EE, Li HP, Costea A, Attari M, Baughman RP. Cardiac Sarcoidosis: The Impact of Age and Implanted Devices on Survival. Chest. 2017 Jan;151(1):139-148. doi: 10.1016/j.chest.2016.08.1457. Epub 2016 Sep 8.

Reference Type DERIVED
PMID: 27614001 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

UCincinnati

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Mepolizumab in Nasal Polyposis
NCT01362244 COMPLETED PHASE2
CST1-Guided Oral Glucocorticoids Management for CRSwNP
NCT05598411 NOT_YET_RECRUITING PHASE4
Evaluation of Inhaled Treatment in Sinusitis
NCT01907204 COMPLETED PHASE2/PHASE3